



Creating anti-infective opportunities

“Patients are at the heart
of what we do”

INVESTOR PRESENTATION

February 18, 2025



Introducing Basilea and the executive management team

- Founded in 2000 as a spin off from Roche
- Profitable Swiss commercial-stage biopharmaceutical company
- About 160 employees
- Headquarters in Allschwil, Switzerland, in the Basel area life sciences hub
- Listed on the SIX Swiss Stock Exchange, Ticker: BSLN.SW



DAVID VEITCH
CEO



ADESH KAUL
CFO



MARC ENGELHARDT
MD, PH.D. CMO



GERRIT HAUCK
PH.D. CTO



**LAURENZ
KELLENBERGER**
PH.D. CSO

JOINED

2014

2009

2010

2018

2000

PREVIOUS
ROLES



"Our experienced team brings deep expertise across Basilea's entire value chain."

Our focus is on identifying and generating commercial opportunities in the anti-infectives area

- We are focused on developing treatments for **severe bacterial and fungal diseases**
- Unmet medical needs:
 - Therapies with limited spectrum of activity
 - Growing resistance
 - Lack of oral dosing forms
 - Toxicities
- We strive to create sustainable value with meaningful benefits for patients and healthcare systems, generating long-term returns for investors and our partners
- Currently two revenue generating hospital anti-infective brands: Cresemba® and Zevtera®




Manifestations of severe infections

<i>Candida spp.</i>	Bloodstream, abdominal, osteoarticular, cardiac, ocular, CNS, pulmonary
<i>Aspergillus spp.</i>	Pulmonary, sinuorbital, CNS, cardiac, cutaneous, abdominal
<i>Fusarium spp.</i>	Bloodstream, cutaneous, sinuorbital, ocular, CNS, pulmonary
Mucorales fungi	Pulmonary, sinuorbital, CNS, renal, cutaneous, abdominal
Staphylococci	Bloodstream, cutaneous, cardiac, abdominal, osteoarticular, pulmonary
Enterobacteriaceae	Bloodstream, urinary, pulmonary, cutaneous, abdominal, osteoarticular

Business model

Unique capabilities, limited acquisition and development costs,
commercialization partnerships supporting profitability

External pool of
potential assets



Healthcare systems are spending > USD 20 billion for systemic antifungals and antibiotics

GLOBAL SYSTEMIC ANTIFUNGALS MARKET 2023

USD
4.4
billion

GLOBAL SYSTEMIC HOSPITAL ANTIBIOTICS MARKET 2023

USD
17.8
billion

Source: IQVIA Analytics Link 2023

Invasive fungal and severe bacterial infections are on the rise due to several factors




Aging population (e.g. elderly individuals more prone to infections)



Growing population of immunocompromised individuals (e.g. patients with chronic conditions)



Advances in **medical procedures** (e.g. medical devices like catheters or other foreign body materials)



Increased use of **immunosuppressive therapies** (e.g. for organ or stem cell transplants, **cancer therapies**, **biologic agents**)



Agriculture: widespread use of fungicides in agriculture




Increasing **resistance** against currently used antibiotics and antifungals



Climate change (e.g. growing incidence of fungal infections)

Commercially successful hospital antifungals have achieved peak sales of ~ 600-900 USD million



- Sales of branded antifungals typically peak around the time of their loss of exclusivity (more than 10 years market opportunity)
- Basilea's Cresemba is already today achieving more than USD 500 million annual sales with continued strong double-digit year on year growth

CDC’s antimicrobial resistance threats in the US

Basilea’s pipeline provides treatment options across all 3 threat levels

Urgent Threats

These germs are public health threats that require urgent and aggressive action:

- Carbapenem-resistant *Acinetobacter*
- Candida auris*
- Clostridioides difficile*
- Carbapenem-resistant *Enterobacteriaceae*
- Drug-resistant *Neisseria gonorrhoeae*

Serious Threats

These germs are public health threats that require prompt and sustained action:

- Drug-resistant *Campylobacter*
- Drug-resistant *Candida*
- ESBL-producing *Enterobacteriaceae*
- Vancomycin-resistant *Enterococci*
- Multidrug-resistant *Pseudomonas aeruginosa*
- Drug-resistant *Nontyphoidal salmonella*
- Drug-resistant *Shigella*
- Methicillin-resistant *Staphylococcus aureus*
- Drug-resistant *Streptococcus pneumoniae*
- Drug-resistant Tuberculosis

Concerning Threats

These germs are public health threats that require careful monitoring and prevention action:

- Erythromycin-resistant *Group A streptococcus*
- Clindamycin-resistant *Group B streptococcus*

Watch list

- Azole-resistant *Aspergillus fumigatus*
- Drug-resistant *Mycoplasma genitalium*
- Drug-resistant *Bordetella pertussis*

Visualized based on CDC Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019. www.cdc.gov/DrugResistance/Biggest-Threats.html (electronic version)

Innovative anti-infective pipeline

Products / Product candidates / Indications	Preclinical	Phase 1	Phase 2	Phase 3	Market
ANTIFUNGALS					
Cresemba® isavuconazole Invasive aspergillosis and mucormycosis (US, EU and several other countries) ¹ Aspergillosis, (including invasive aspergillosis and chronic pulmonary aspergillosis), mucormycosis and cryptococcosis (Japan)					
Fosmanogepix Candidemia / invasive candidiasis (including <i>Candida auris</i>) Invasive mold infections (including invasive aspergillosis, fusariosis, <i>Scedosporium</i> and <i>Lomentospora</i> , mucormycosis and other rare mold infections)					
BAL2062 Invasive aspergillosis					
ANTIBACTERIALS					
Zevtera® ceftobiprole Hospital- and community-acquired bacterial pneumonia (HABP, CABP) (major European and several other countries) <i>Staphylococcus aureus</i> bacteremia (SAB), acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) (United States)					
BAL2420 (LptA inhibitor) Severe Enterobacteriaceae infections					
Internal research					
Focus for in-licensing and acquisitions					

¹ The registration status and approved indications may vary from country to country.

Non-dilutive R&D funding

BARDA Other Transaction Agreement (OTA)¹

- Flexible contracting mechanism
- Initial commitment of USD 29 million for development of antifungals fosmanogepix and BAL2062
- Potential total funding of up to ~USD 268 million
- Reimbursement of about 60% of the total development cost

CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator)

- Funding agreement for LptA inhibitor antibiotic program²
- Initial funding of up to USD 0.9 million awarded until candidate nomination
- Additional funding of up to USD 7.3 million until first-in-human clinical studies for drug candidate BAL2420

¹ OTA number 75A50124C00033

² Agreement number 75A50122C00028 and WT224842

Anti-infective pipeline

Antifungals



Cresemba — Differentiated by spectrum, safety and tolerability

- Broad spectrum of activity against molds, including emerging molds (Mucorales fungi)
- Consistent plasma levels
- Statistically fewer drug-related adverse events and treatment-emergent adverse events (liver, skin, eye) in invasive aspergillosis patients vs. voriconazole in SECURE phase 3 study
- Can be administered without restriction in patients with renal impairment
- Manageable drug-drug interaction profile
- Once daily maintenance dose, IV/oral treatment
- ECIL-6 guideline: Cresemba® recommended for the first-line treatment of invasive aspergillosis in leukemia and hematopoietic stem cell transplant patients. ECIL states that isavuconazole is as effective as voriconazole with a better safety profile.

Cresemba®


Global commercial partnership

Marketed in
75
countries

United States	
Canada	
Latin America	
Europe (excluding Nordics)	
Nordics	
MENA Region	
Asia-Pacific and China	
Japan	

In-market sales

USD **533** million
in-market sales in the
12 months to September 2024



MAT: Moving annual total; Source: IQVIA Analytics Link, September 2024
Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution


Global sales of best-in-class antifungals* by product

USD 2.8 billion sales (MAT Q3 2024)

Significant potential to increase Cresemba® (isavuconazole) global market share

- Pediatric label extension in US granted in December 2023; market exclusivity extended to September 2027
- Pediatric label extension in EU granted in August 2024; market exclusivity extended to October 2027


* Best-in-class antifungals: Cresemba (isavuconazole), posaconazole, voriconazole, liposomal Amp B, anidulafungin, caspofungin, micafungin, rezafungin



MAT: Moving annual total; Source: IQVIA Analytics Link, September 2024, rounding consistently applied

Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution


Cresemba – the market leader in the US in terms of value



- Consistently increased market share among best-in-class antifungals* since launch to 44% by September 2024**

* Best-in-class antifungals: Cresemba (isavuconazole), posaconazole, voriconazole, liposomal Amp B, anidulafungin, caspofungin, micafungin, rezafungin

Significant global growth potential





- USD 2.8 billion sales of best-in-class antifungals* (MAT Q3 2024)**
- Recently launched in Japan and China, representing 21% of global potential

**Market share based on MAT Q3 2024, in-market sales reported as moving annual total (MAT) in US dollar; rounding consistently applied. Source: IQVIA Analytics Link, September 2024

Fosmanogepix – Mannoprotein Anchoring Pathway Inhibitor

- Manogepix acts on the Gwt1 enzyme and disrupts the anchoring of membrane and cell wall proteins
- Effects of Gwt1 inhibition include:
 - Decrease fungal pathogenicity
 - Reduce fungal cell viability
 - Promote cell death
 - Reduction in biofilm formation
 - Clear fungal infections



Fosmanogepix – Potent broad-spectrum activity

	Fosmanogepix	Ibrexafungerp	Olorofim	Rezafungin
	IV and Oral	Oral	Oral	IV
Fungal pathogens				
<i>Candida spp.*</i>	●	●	●	●
<i>Aspergillus spp.†</i>	●	●	●	●
<i>Mucorales‡</i>	●	●	●	
<i>Fusarium spp.</i>	●	●	●	
<i>Scedosporium spp.</i>	●	●	●	
<i>Lomentospora spp.</i>	●	●	●	
<i>Cryptococcus spp.</i>	●		●	●
Endemic molds§	●		●	
Other rare molds	● ● ● ● ● ●	● ● ● ● ●	● ● ● ● ●	
Other rare yeasts¶	●	●	●	

Potent activity

Variable activity

No activity

Unknown

* including *C. albicans*, *C. auris*, *C. dubliniensis*, *C. glabrata*, *C. krusei*, *C. lusitanae*, *C. parapsilosis*, *C. tropicalis*. Fosmanogepix not active against *C. krusei*.

† including *A. calidoustus*, *A. fumigatus* (including azole-resistant), *A. flavus*, *A. lentulus*, *A. nidulans*, *A. niger*, *A. terreus*, *A. tubingensis*.

‡ including *Cunninghamella spp.*, *Lichtheimia spp.*, *Mucor spp.*, *Rhizopus spp.*

§ including *Blastomyces dermatitidis*, *Coccidioides immitis*, *Histoplasma capsulatum*.

|| including *Alternaria alternata*, *Cladosporium spp.*, *Paecilomyces variotii*, *Purpureocillium lilacinum*, *Scopulariopsis spp.*, *Rasamsonia spp.*

¶ including *Trichosporon asahii*, *Exophiala dermatitidis*, *Malassezia furfur*.

Adapted from Hoenigl M, Sprute R, Egger M et al. Drugs. 2021;81:1703-1729.

Fosmanogepix – Global phase 3 program

Candidemia / Invasive candidiasis



- Randomized, double-blind, non-inferiority study
 - Approximately 450 patients
- Fosmanogepix IV (oral step-down fosmanogepix) vs caspofungin IV (oral step-down to fluconazole)
- Primary endpoints
 - FDA: Survival at 30 days
 - EMA: Overall response at end-of-study treatment
- Study ongoing

Invasive mold infections (IMI)



- Randomized, open-label study including non-controlled salvage treatment arm
 - Approximately 200 patients
- Cohorts of invasive mold disease including IMI caused by:
 - *Aspergillus* spp.
 - *Fusarium* spp.
 - *Scedosporium* spp.
 - *Lomentospora prolificans*
 - Mucorales, or
 - Other molds (salvage)
- Fosmanogepix IV or oral vs best available therapy
- Endpoints include survival and overall response
- Expected study start in Q2 2025

QIDP and Fast Track designations by the FDA for invasive candidiasis, invasive aspergillosis, scedosporiosis, fusariosis, mucormycosis, cryptococcosis, and coccidioidomycosis

BAL2062 – For the treatment of invasive aspergillosis

PLACE IN THERAPY

First-line IV treatment of invasive aspergillosis (incl. azole-resistant) with the potential to deliver superior efficacy to standard-of-care

KEY ATTRIBUTES

- New mode of action
- No cross-resistance
- Rapidly fungicidal
- Potential for superior efficacy
- No renal toxicity
- No DDIs expected

STATUS & NEXT STEPS

- Preclinical profiling studies ongoing
- Preparation of the phase 2 program in 2025 to start the study in 2026



Anti-infective pipeline

Antibacterials

Zevtera® — An introduction

- Broad-spectrum hospital anti-MRSA cephalosporin (including Gram-negative bacteria)
 - Rapid bactericidal activity
 - Potential to replace antibiotic combinations
 - Efficacy demonstrated in phase 3 clinical studies in SAB, ABSSSI and pneumonia^{1, 2, 3}
 - Low propensity for resistance development¹
 - Safety profile consistent with the cephalosporin class safety profile, demonstrated in both adult and pediatric patients^{1, 2, 3, 4}
- Marketed in selected countries in Europe, Latin America, the MENA-region, Canada and China
- US launch expected mid-2025

Approved in major European countries & several non-European countries for both hospital-acquired bacterial pneumonia (HABP), excluding ventilator-associated pneumonia (VAP), and community-acquired bacterial pneumonia (CABP). Indicated in the US for the treatment of adult patients with *Staphylococcus aureus* bloodstream infections (bacteremia) (SAB), including right-sided infective endocarditis, and adult patients with acute bacterial skin and skin structure infections (ABSSSI) and for adult and pediatric patients (3 months to less than 18 months old) with community-acquired bacterial pneumonia (CABP).



¹ Syed YY. Drugs. 2014;74:1523-1542 and Basilea data on file.


² Overcash JS et al. Clin Infect Dis. 2021;73:e1507-e1517.

³ Holland TL et al. N Engl J Med. 2023;389:1390-1401.

⁴ Rubino CM et al. Pediatr Infect Dis J. 2021;40:997-1003.

Hospital anti-MRSA antibiotics – US being the most important commercial opportunity

Daptomycin sales by region (2015, before LOE)



MRSA: Methicillin-resistant *Staphylococcus aureus*; LOE: Loss of exclusivity; ROW: Rest Of World; MAT: Moving annual total; Source: IQVIA Analytics Link, September 2024

Zevtera — Strategy for accessing the US market

- Commercialization through partner:

INNOCIVA Specialty Therapeutics

- Preparing for commercial launch mid-2025
 - Launch material manufactured
 - Field force training in preparation
- Qualified Infectious Disease Product (QIDP) designation extends US market exclusivity to 10 years from approval

Zevtera — Place in therapy

- Excellent treatment option in difficult-to-treat patients presenting to the hospital with severe infections, especially when the clinician suspects involvement of Gram-positive pathogens including *Staphylococcus aureus*
- Single agent first-line bactericidal broad-spectrum therapy with proven efficacy in SAB, ABSSSI and CABP, enabling to treat these vulnerable patients effectively early in their disease to achieve recovery
- Ceftobiprole is differentiated versus competitors in various clinically important aspects, including:
 - The strong, bactericidal activity against MSSA and MRSA
 - A robust Gram-negative coverage
 - Efficacy demonstrated in pulmonary infections in phase 3 studies
 - The safety profile reflecting the cephalosporin class
 - The low propensity for resistance development

BAL2420 (LptA inhibitor) – Next generation first-in-class antibacterial

PLACE IN THERAPY

New treatment option for the most frequent Gram-negative pathogens causing bloodstream infections (Enterobacteriaceae), including carbapenem-resistant isolates

KEY ATTRIBUTES

- New mode of action
- Bactericidal
- Highly potent
- No cross-resistance to other antibiotic classes

STATUS & NEXT STEPS

- Acquired LptA inhibitor program in January 2024
- Nominated BAL2420 as drug candidate
- Progressing towards first-in-human clinical study in mid-2026



Financials & Outlook

Consolidated financial statements Basilea Pharmaceutica Ltd, Allschwil			
Consolidated balance sheets			
	Footnote	2024	2023
In CHF thousands, except for number of shares			
ASSETS			
CURRENT ASSETS			
Cash and cash equivalents	6	72 271	59 353
Restricted cash	6	7 269	4 589
Accounts receivable	7	49 083	27 891
Other receivables	8	31 800	30 257
Inventories, net	9	25 604	26 410
Other assets	10	8 463	3 265
Total current assets		191 490	152 165
NON-CURRENT ASSETS			
Property, plant and equipment, net	2	3 339	3 757
Operating lease right-of-use assets, net	3	16 439	16 795
Intangible assets, net	4	422	548
Other assets	5	224	43
Deferred tax assets	11	19 564	21 144
Total non-current assets		20 588	21 247
TOTAL ASSETS		212 078	173 412
LIABILITIES			
CURRENT LIABILITIES			
Accounts payable	12	11 666	5 152
Accounts secured loan	13	-	5 403
Senior secured loan	14	1 223	1 126
Operating lease liabilities	15	2 048	2 248
Deferred revenue	16	4 571	12 788
Accruals and other current liabilities	17	31 502	6 786
Total current liabilities		19 410	33 693
NON-CURRENT LIABILITIES			
Convertible senior secured loan	18	95 798	95 402
Deferred revenue	19	8 534	3 460
Operating lease liabilities	20	14 200	15 426
Other liabilities	21	4 476	15 782
Total non-current liabilities		123 008	130 070
TOTAL LIABILITIES		142 418	163 763
SHAREHOLDERS' EQUITY (DEFICIT)			
Share capital	22	15 725	15 725
Treasury shares	23	(31 443)	(34 238)
Additional paid-in capital	24	1 044 223	1 044 223
Accumulated other comprehensive loss	25	(9 066)	(9 202)
Accumulated deficit	26	(1 090 886)	(1 091 333)
Loss carried forward	27	67 636	70 485
Net profit for the year	28	66 696	(26 128)
Total shareholders' equity (deficit)		120 669	121 269
TOTAL LIABILITIES AND EQUITY		212 078	173 412

These financial statements should be read in conjunction with the footnotes.

* As of December 31, 2024, 12,099,406 shares (December 31, 2023: 12,099,406) were issued and 12,099,406 shares (December 31, 2023: 12,099,406) were outstanding with a par value of CHF 100 per share.
* As of December 31, 2024, 1,098,307 shares (December 31, 2023: 1,098,307) with a par value of CHF 100.


Consolidated statements of operations Basilea Pharmaceutica Ltd, Allschwil & subsidiaries for the years ended December 31, 2024 and 2023			
	Footnote	2024	2023
In CHF thousands, except for share options			
Product revenue	29	45 076	37 911
Contract revenue	30	104 768	103 364
Other revenue	31	4 951	7 359
Total revenue		154 895	148 634
Cost of products sold	32	(30 734)	(26 754)
Research & development expenses, net	33	(97 285)	(171 852)
Selling, general & administrative expenses	34	(22 905)	(33 703)
Other components of net periodic pension cost	35	(336 856)	(336 830)
Total cost and operating expenses		(647 779)	(642 149)
Operating result		15 116	939
Interest income	36	1 442	1 632
Other income	37	201	2 400
Other components of net periodic pension cost	38	48 925	48 925
Profit before taxes		19 544	19 544
Income taxes	39	(67 636)	(67 636)
Net profit		12 908	12 908
Net profit attributable to shareholders		12 908	12 908
Net profit attributable to non-controlling interests		-	-
Net profit attributable to all shareholders		12 908	12 908

Strong financial results FY 2024 – Significant increase in revenue and profit


in CHF million	FY 2023	FY 2024	Guidance FY 2024
Cresemba and Zevtera related revenue	150.3	194.9	190
of which royalty income	78.9	96.7	
of which milestone and upfront payments	33.5	40.4	
Other revenue	7.4	13.7	13
Total revenue	157.6	208.5	203
Cost of products sold	26.8	38.7	
Operating expenses	111.7	108.6	
Operating profit	19.2	61.2	43
Net profit	10.5	77.6	60
Net financial debt / Net cash (as of December 31, 2024/2023)	-46.6	28.6	

Note: Consolidated figures in conformity with US GAAP; rounding applied consistently

Cresemba and Zevtera related revenue – Continued double-digit growth in royalty income, reflecting strong in-market demand




Significant increase in cash flows from operating activities (in CHF million)



Note: Consolidated figures in conformity with US GAAP; rounding applied consistently

CHF 124 million reduction of debt level 2022 – 2025



FY 2025 financial guidance – Significantly growing royalty income, maintaining high operating profit while increasing R&D investments

in CHF million	FY 2025 (guidance)	FY 2024 (actuals)
Cresamba and Zevtera related revenue	~190	194.9
<i>of which royalty income</i>	<i>~110</i>	<i>96.7</i>
Total revenue	~220	208.5
Research and development expenses	~88	77.1
Operating profit	~62	61.2

Note: Consistent rounding was applied.

Key value drivers 2025

- Increasing Cresemba & Zevtera revenue
 - US launch of Zevtera
- Advancement of preclinical and clinical anti-infective assets
 - Start of second phase 3 study with fosmanogepix (mold infections)
- In-licensing and acquisition of additional anti-infective assets
- Continue to access non-dilutive R&D funding for anti-infectives portfolio

Disclaimer and forward-looking statements

This communication, including the accompanying oral presentation, contains certain forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “supposes”, “considers”, and words of similar import, or which can be identified as discussions of strategy, plans or intentions. Such forward-looking statements are based on the current expectations and belief of company management, and are subject to numerous risks and uncertainties, which may cause the actual results, financial condition, performance, or achievements of Basilea, or the industry, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the uncertainty of pre-clinical and clinical trials of potential products, limited supplies, future capital needs and the uncertainty of additional funding, compliance with ongoing regulatory obligations and the need for regulatory approval of the company’s operations and potential products, dependence on licenses, patents, and proprietary technology as well as key suppliers and other third parties, including in preclinical and clinical trials, acceptance of Basilea’s products by the market in the event that they obtain regulatory approval, competition from other biotechnology, chemical, and pharmaceutical companies, attraction and retention of skilled employees and dependence on key personnel, and dependence on partners for commercialization of products, limited manufacturing resources, management’s discretion as to the use of proceeds, risks of product liability and limitations on insurance, uncertainties relating to public health care policies, adverse changes in governmental rules and fiscal policies, changes in foreign currency and other factors referenced in this communication. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. Basilea disclaims any obligation to update any such forward-looking statements to reflect future events or developments, except as required by applicable law.



Peer Nils Schröder, PhD

Head of Corporate Communications
& Investor Relations

Basilea Pharmaceutica International Ltd, Allschwil
Hegenheimermattweg 167b
4123 Allschwil | Switzerland

Phone	+41 61 606 1102
E-mail	investor_relations@basilea.com

Glossary

- ABSSSI: **A**cute **b**acterial **s**kin and **s**kin **s**tructure infections
- BARDA: **B**iomedical **A**dvanced **R**esearch and **D**evelopment **A**uthority
- CABP: **C**ommunity-**a**cquired **b**acterial **p**neumonia
- CARB-X: **C**ombating **A**ntibiotic-**R**esistant **B**acteria Biopharmaceutical **A**ccelerator
- CNS: **C**entral **N**ervous **S**ystem
- CYP: **C**ytochrome **P**
- DDI: **D**rug-**d**rug interaction
- EMA: **E**uropean **M**edicines **A**gency
- FDA: **U**S **F**ood and **D**rug **A**dministration
- Gwt-1: **G**PI-anchored **w**all **t**ransfer protein **1**
- HABP: **H**ospital-**a**cquired **b**acterial **p**neumonia
- IMI: **I**nvasive **m**old infections
- IV: **I**ntravenous
- MRSA: **M**ethicillin-**r**esistant **S**taphylococcus **a**ureus
- MS-DRG: **M**edicare **S**everity **D**iagnosis-**R**elated **G**roup
- MSSA: **M**ethicillin-**s**usceptible **S**taphylococcus **a**ureus
- QIDP: **Q**ualified **I**nfectious **D**isease **P**roduct
- SAB: **S**taphylococcus **a**ureus **b**acteremia
- US GAAP: **U**nited **S**tates **G**enerally **A**ccepted **A**ccounting **P**riniples
- VAP: **V**entilator-**a**ssociated **p**neumonia



**Creating anti-infective
opportunities**

**Hegenheimermattweg 167b
4123 Allschwil
Switzerland**

**info@basilea.com
www.basilea.com**

All rights reserved.
© 2025 Basilea Pharmaceutica International Ltd, Allschwil